Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.
about
Vaccines for the common coldUse of licensed vaccines for active immunization of the immunocompromised hostInfectious diseases: annual review of significant publications.Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachAdenoviruses in lymphocytes of the human gastro-intestinal tractImmune evasion by adenoviruses.Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development.Genomic and bioinformatics analyses of HAdV-4vac and HAdV-7vac, two human adenovirus (HAdV) strains that constituted original prophylaxis against HAdV-related acute respiratory disease, a reemerging epidemic disease.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersControl of adenovirus acute respiratory disease in U.S. Army trainees.History of vaccinationImmunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirusFoot-and-mouth disease.Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.Re-emergent human adenovirus genome type 7d caused an acute respiratory disease outbreak in Southern China after a twenty-one year absence.A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Respiratory Infections in the U.S. Military: Recent Experience and ControlConcepts and strategies for human gene therapy.Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challengeSafety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashionIsolation and characterization of temperature-sensitive mutants of adenovirus type 7.A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.Molecular evolution of human species D adenoviruses.Prospects for oral replicating adenovirus-vectored vaccines.Vaccines for the common cold.The success of microneedle-mediated vaccine delivery into skin.Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.Construction of an adenovirus type 7a E1A- vector.Adenovirus pneumoniaReplication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.Introduction acute respiratory infections in military personnel.
P2860
Q24201977-4A8BBA49-E8D5-46E1-AE30-2775D497DB52Q24533456-EAE41979-CE3D-4FB4-8FA3-E4D0C6961242Q27486591-F59E4E6B-5FD4-4998-B3AE-60568B237F8CQ28607775-7F363ED0-8951-448B-8A3E-A752B5FB19F2Q28744382-5CACF8F9-3952-4ED4-BCEC-A8768456FA87Q33683353-EDDC1916-BAAB-4A57-9B3F-17AA4E587481Q33781719-E77543BB-0601-4687-8421-BBFBC3595A4FQ33885233-B95DFE21-029E-4013-AC8E-21F0E76E2267Q33985663-FA81BA4E-964F-49D5-A8CA-D5EBEB201EF5Q34040015-D06F8138-8316-43FB-A9E7-29A14232C8B0Q34119899-EB435ECA-4BE0-47C9-90A3-1AD4444FF3DAQ34301871-B0A939AE-684D-418F-B269-BA1FB25B5C1EQ34547126-27D8FD8C-11B0-4942-A818-63DC17EE8725Q34636530-FBD76DA8-A323-43DE-B47D-962A7B7D6FFAQ34648168-1D15E3CC-4A48-48A7-83EB-93654841424DQ34889790-D59E2FE9-7AAE-4929-BE99-6216286A1D37Q35160124-6B72E777-61FB-4018-BDE9-4469C09F6E9AQ35182076-FE940D7D-453A-46CA-9318-5BF6F86C0DBDQ35763405-00C06569-7CD0-46E2-95AC-2581CCB29C10Q35816188-7F8A69D7-7DDB-4137-8B46-E69FC1BB20EFQ35826388-622B75BC-8AA7-4A9D-B075-311CAC01A3D6Q35883639-FA3A246E-AE10-4B8C-AF7E-B7E099EA4783Q35898573-FFDDFB4C-0586-46FC-ABF8-8272FB4A72FAQ36225504-D23AB1AC-4546-4E8C-A1A0-E06310690EFBQ36427024-4FDD640C-205A-481D-B9AC-CEFA1A54446DQ36504789-1470CCE2-E22C-492D-9037-FA7C699E5D1BQ36685348-50CB763D-C4FA-4024-8A26-4F15FCB34093Q36829259-58E132AF-CD73-43BC-9FC6-53A6025DF821Q36919176-8BB69E4F-674C-4AF9-B05E-EEC83C457E76Q37812291-3C7FA936-038E-42BE-B0AC-E7CD8C1F1151Q37875388-CC2CFFDE-2B7F-4290-9AD2-A96EE9A66E3FQ38109356-5F276880-191F-4B43-BBC1-E7428992DBC0Q38682527-5D4EBC9D-4FC5-4937-AA19-CCD2EB1FCD71Q38799509-24C46D27-328D-4481-8572-E9C3E3670877Q39598811-349C08D4-8A0D-497C-B578-DAA62D9592B1Q39876527-1A06787C-18FD-4FDA-A491-C587E4ECA40DQ39882405-2A610666-C14B-43A8-8536-64D672206FF2Q39897261-78FC2629-E03B-4505-BCDF-17551F4EBF56Q40012391-8B1A1D4A-FCED-466E-9C1F-34BD026B6512Q41233134-7FD393F6-101F-4A12-9D74-380BB3B6B5EC
P2860
Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.
description
1971 nî lūn-bûn
@nan
1971年の論文
@ja
1971年学术文章
@wuu
1971年学术文章
@zh-cn
1971年学术文章
@zh-hans
1971年学术文章
@zh-my
1971年学术文章
@zh-sg
1971年學術文章
@yue
1971年學術文章
@zh
1971年學術文章
@zh-hant
name
Immunization with live types 7 ...... ease due to adenovirus type 7.
@en
Immunization with live types 7 ...... ease due to adenovirus type 7.
@nl
type
label
Immunization with live types 7 ...... ease due to adenovirus type 7.
@en
Immunization with live types 7 ...... ease due to adenovirus type 7.
@nl
prefLabel
Immunization with live types 7 ...... ease due to adenovirus type 7.
@en
Immunization with live types 7 ...... ease due to adenovirus type 7.
@nl
P2093
P921
P356
P1476
Immunization with live types 7 ...... ease due to adenovirus type 7.
@en
P2093
Bancroft WH
Buescher EL
Russell PK
P304
P356
10.1093/INFDIS/124.2.155
P407
P577
1971-08-01T00:00:00Z